Samy Suissa

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/3008748/samy-suissa-publications-by-year.pdf

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

14,226 264 113 59 h-index g-index citations papers 16,946 284 7.2 7.3 L-index avg, IF ext. citations ext. papers

#	Paper	IF	Citations
264	Proton pump inhibitors and risk of gastric cancer: population-based cohort study. <i>Gut</i> , 2022 , 71, 16-24	19.2	10
263	Proton pump inhibitors and risk of colorectal cancer. <i>Gut</i> , 2022 , 71, 111-118	19.2	5
262	The quintessence of causal DAGs for immortal time bias: time-dependent models <i>International Journal of Epidemiology</i> , 2022 ,	7.8	1
261	Fluticasone-Based versus Budesonide-Based Triple Therapies in COPD: Real-World Comparative Effectiveness and Safety <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2022 , 19, 109-117	2	
260	Discontinuation of Inhaled Corticosteroids from Triple Therapy in COPD: Effects on Major Outcomes in Real World Clinical Practice <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2022 , 19, 133-141	2	O
259	Single-arm Trials with Historical Controls: Study Designs to Avoid Time-related Biases. <i>Epidemiology</i> , 2021 , 32, 94-100	3.1	2
258	Advanced Approaches to Controlling Confounding in Pharmacoepidemiologic Studies 2021 , 368-385		
257	Comparing initial LABA-ICS inhalers in COPD: Real-world effectiveness and safety. <i>Respiratory Medicine</i> , 2021 , 189, 106645	4.6	3
256	Risk of fracture in patients with non-valvular atrial fibrillation initiating direct oral anticoagulants vs. vitamin K antagonists. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021 , 7, 389-397	6.4	3
255	Mortality benefit with antifibrotics in idiopathic pulmonary fibrosis: real world evidence or bias?. <i>European Respiratory Journal</i> , 2021 , 57,	13.6	О
254	Comparison of Pregnancy Outcomes of Patients Treated With Ondansetron vs Alternative Antiemetic Medications in a Multinational, Population-Based Cohort. <i>JAMA Network Open</i> , 2021 , 4, e21	5 329	3
253	Infectious Disease Burden and the Risk of Alzheimer's Disease: A Population-Based Study. <i>Journal of Alzheimerm Disease</i> , 2021 , 81, 329-338	4.3	4
252	Allopurinol and cardiovascular events: Time-related biases in observational studies. <i>Arthritis Care and Research</i> , 2021 ,	4.7	1
251	Reply. Arthritis and Rheumatology, 2021 , 73, 2349	9.5	
250	Statins and lower mortality in rheumatic diseases: An effect of immortal time bias?. <i>Seminars in Arthritis and Rheumatism</i> , 2021 , 51, 211-218	5.3	3
249	Comparing New-User Cohort Designs: The Example of Proton Pump Inhibitor Effectiveness in Idiopathic Pulmonary Fibrosis. <i>American Journal of Epidemiology</i> , 2021 , 190, 928-938	3.8	3
248	Effectiveness of Proton Pump Inhibitors in Idiopathic Pulmonary Fibrosis: A Population-Based Cohort Study. <i>Chest</i> , 2021 , 159, 673-682	5.3	7

(2020-2021)

247	Comparative Effectiveness of Initial LAMA versus LABA in COPD: Real-World Cohort Study. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2021 , 18, 1-8	2	7
246	The Rgie de lassurance maladie du Qubec (RAMQ) Databases. <i>Springer Series on Epidemiology and Public Health</i> , 2021 , 215-230	0.4	O
245	Biases in Evaluating the Safety and Effectiveness of Drugs for the Treatment of COVID-19: Designing Real-World Evidence Studies. <i>American Journal of Epidemiology</i> , 2021 , 190, 1452-1456	3.8	9
244	Effectiveness of Aspirin in COPD: Biases in the Observational Studies. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2021 , 18, 449-455	2	
243	Effectiveness of Allopurinol in Reducing Mortality: Time-Related Biases in Observational Studies. <i>Arthritis and Rheumatology</i> , 2021 , 73, 1749-1757	9.5	4
242	Perplexing mortality data from triple therapy trials in COPD. Lancet Respiratory Medicine,the, 2021 , 9, 684-685	35.1	6
241	Triple Therapy in COPD: Time for Adaptive Selection Trials. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2021 , 1-5	2	1
240	Triple Inhaler versus Dual Bronchodilator Therapy in COPD: Real-World Effectiveness on Mortality. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2021 , 1-9	2	3
239	Ten Commandments for Randomized Trials of Pharmacological Therapy for COPD and Other Lung Diseases. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2021 , 18, 485-492	2	
238	Withdrawal of inhaled corticosteroids in COPD: a European Respiratory Society guideline. <i>European Respiratory Journal</i> , 2020 , 55,	13.6	48
237	Response. <i>Chest</i> , 2020 , 157, 1395-1396	5.3	
236	Mortality in IMPACT: Confounded by Asthma?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020 , 202, 772-773	10.2	5
235	Avoiding immortal time bias in observational studies. European Respiratory Journal, 2020, 55,	13.6	2
234	Response. <i>Chest</i> , 2020 , 157, 1045-1046	5.3	
233	Aromatase Inhibitors and the Risk of Cardiovascular Outcomes in Women With Breast Cancer: A Population-Based Cohort Study. <i>Circulation</i> , 2020 , 141, 549-559	16.7	34
232	Emulation Differences vs. Biases When Calibrating Real-World Evidence Findings Against Randomized Controlled Trials. <i>Clinical Pharmacology and Therapeutics</i> , 2020 , 107, 735-737	6.1	9
231	The European MultiPartner IPF registry (EMPIRE): validating long-term prognostic factors in idiopathic pulmonary fibrosis. <i>Respiratory Research</i> , 2020 , 21, 11	7.3	18
230	Cardiotoxicity of Use of Sequential Aromatase Inhibitors in Women With Breast Cancer. <i>American Journal of Epidemiology</i> , 2020 , 189, 1086-1095	3.8	6

229	Comparative safety of biologic versus conventional synthetic DMARDs in rheumatoid arthritis with COPD: a real-world population study. <i>Rheumatology</i> , 2020 , 59, 820-827	3.9	2
228	Healthcare Database Networks for Drug Regulatory Policies: International Workshop on the Canadian, US and Spanish Experience and Future Steps for Italy. <i>Drug Safety</i> , 2020 , 43, 1-5	5.1	7
227	Improving the Efficiency of Randomized Trials: The DYNAGITO Example. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2020 , 17, 4-6	2	2
226	The Canadian Network for Observational Drug Effect Studies (CNODES): Reflections on the first eight years, and a look to the future. <i>Pharmacoepidemiology and Drug Safety</i> , 2020 , 29 Suppl 1, 103-107	2.6	9
225	Comparative Effects of LAMA-LABA-ICS vs LAMA-LABA for COPD: Cohort Study in Real-World Clinical Practice. <i>Chest</i> , 2020 , 157, 846-855	5.3	34
224	Inhaled corticosteroid use and the incidence of lung cancer in COPD. <i>European Respiratory Journal</i> , 2020 , 55,	13.6	10
223	Response. <i>Chest</i> , 2020 , 158, 832-833	5.3	
222	Sodium-Glucose Cotransporter 2 Inhibitors and the Risk of Below-Knee Amputation: A Multicenter Observational Study. <i>Diabetes Care</i> , 2020 , 43, 2444-2452	14.6	13
221	Time-related biases in pharmacoepidemiology. <i>Pharmacoepidemiology and Drug Safety</i> , 2020 , 29, 1101-	11.160	22
220	Sodium glucose cotransporter 2 inhibitors and risk of major adverse cardiovascular events: multi-database retrospective cohort study. <i>BMJ, The</i> , 2020 , 370, m3342	5.9	28
219	Response by Khosrow-Khavar et al to Letters Regarding Article, "Aromatase Inhibitors and the Risk of Cardiovascular Outcomes in Women With Breast Cancer: A Population-Based Cohort Study". <i>Circulation</i> , 2020 , 142, e158-e159	16.7	
218	Comparative cardiovascular and hypoglycaemic safety of glimepiride in type 2 diabetes: A population-based cohort study. <i>Diabetes, Obesity and Metabolism</i> , 2020 , 22, 254-262	6.7	2
217	Response. <i>Chest</i> , 2019 , 156, 416-417	5.3	
216	Abatacept initiation in rheumatoid arthritis and the risk of serious infection: A population-based cohort study. <i>Seminars in Arthritis and Rheumatism</i> , 2019 , 48, 1053-1058	5.3	9
215	Association of Aripiprazole With the Risk for Psychiatric Hospitalization, Self-harm, or Suicide. JAMA Psychiatry, 2019 , 76, 409-417	14.5	82
214	Re-evaluating Safety and Effectiveness of Dabigatran Versus Warfarin in a Nationwide Data Environment: A Prevalent New-User Design Study. <i>Drugs - Real World Outcomes</i> , 2019 , 6, 93-104	2.2	5
213	Triple therapy in COPD: only for the right patient. European Respiratory Journal, 2019, 53,	13.6	5
212	Comparative safety of abatacept in rheumatoid arthritis with COPD: A real-world population-based observational study. <i>Seminars in Arthritis and Rheumatism</i> , 2019 , 49, 366-372	5.3	7

Risk of Malignant Cancers in Inflammatory Bowel Disease. Journal of Crohnmand Colitis, 2019, 13, 1302-1340 211 Comparative Effectiveness and Safety of LABA-LAMA vs LABA-ICS Treatment of COPD in 210 36 5.3 Real-World Clinical Practice. Chest, 2019, 155, 1158-1165 Sulfonylureas as initial treatment for type 2 diabetes and the risk of adverse cardiovascular events: 3.8 209 17 A population-based cohort study. British Journal of Clinical Pharmacology, 2019, 85, 2378-2389 Advanced Approaches to Controlling Confounding in Pharmacoepidemiologic Studies 2019, 1078-1107 208 Comparative risk of malignancies and infections in patients with rheumatoid arthritis initiating abatacept versus other biologics: a multi-database real-world study. Arthritis Research and Therapy, 207 5.7 14 2019, 21, 228 Inhaled corticosteroids and pneumonia mortality in COPD patients. European Respiratory Journal, 206 13.6 2019, 54, Discussion of Schuemie et al: "A plea to stop using the case-control design in retrospective 205 9 2.3 database studies". Statistics in Medicine, 2019, 38, 4209-4212 Misinterpretation of time-to-first event curves can lead to inappropriate treatment. European 204 13.6 Respiratory Journal, 2019, 54, Control of Confounding and Reporting of Results in Causal Inference Studies. Guidance for Authors from Editors of Respiratory, Sleep, and Critical Care Journals. Annals of the American Thoracic 267 203 4.7 Society, 2019, 16, 22-28 Concomitant Use of Direct Oral Anticoagulants with Antiplatelet Agents and the Risk of Major 202 Bleeding in Patients with Nonvalvular Atrial Fibrillation. American Journal of Medicine, 2019, 132, 191-19 $\frac{22}{6}$ 12 Abatacept initiation in rheumatoid arthritis and the risk of cancer: a population-based comparative 201 3.9 14 cohort study. Rheumatology, 2019, 58, 683-691 How pharmacoepidemiology networks can manage distributed analyses to improve replicability 2.6 18 200 and transparency and minimize bias. Pharmacoepidemiology and Drug Safety, 2019, 29, 3 Non-Vitamin K Antagonist Oral Anticoagulants and Risk of Serious Liver Injury. Journal of the 28 199 15.1 American College of Cardiology, 2018, 71, 1105-1113 Observational Studies of Inhaled Corticosteroid Effectiveness in COPD: Lessons Learned. Chest, 198 5.3 14 2018, 154, 257-265 Comparative effectiveness of novel oral anticoagulants in UK patients with non-valvular atrial 197 3 2.2 fibrillation and chronic kidney disease: a matched cohort study. BMJ Open, 2018, 8, e019638 Mortality Reduction in EMPA-REG OUTCOME Trial: Beyond the Antidiabetes Effect. Diabetes Care, 196 14.6 11 2018, 41, 219-223 Food and Drug Administration-mandated Trials of Long-Acting Edgonist Safety in Asthma. Bang 195 10.2 3 for the Buck?. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 987-990 Lower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias?. Diabetes Care, 78 194 14.6 **2018**, 41, 6-10

193	Proton-pump inhibitors and increased gastric cancer risk: time-related biases. <i>Gut</i> , 2018 , 67, 2228-2229	19.2	16
192	The effect of anti-acid therapy on survival in idiopathic pulmonary fibrosis: a methodological review of observational studies. <i>European Respiratory Journal</i> , 2018 , 51,	13.6	23
191	Trends in initiation of direct oral anticoagulant therapies for atrial fibrillation in a national population-based cross-sectional study in the French health insurance databases. <i>BMJ Open</i> , 2018 , 8, e018180	3	31
190	Reduced Mortality With Sodium-Glucose Cotransporter-2 Inhibitors in Observational Studies: Avoiding Immortal Time Bias. <i>Circulation</i> , 2018 , 137, 1432-1434	16.7	14
189	Long-term Use of Inhaled Corticosteroids in COPD and the Risk of Fracture. <i>Chest</i> , 2018 , 153, 321-328	5.3	42
188	Sulfonylureas as Initial Treatment for Type 2 Diabetes and the Risk of Severe Hypoglycemia. <i>American Journal of Medicine</i> , 2018 , 131, 317.e11-317.e22	2.4	22
187	Sulfonylureas as second line drugs in type 2 diabetes and the risk of cardiovascular and hypoglycaemic events: population based cohort study. <i>BMJ, The</i> , 2018 , 362, k2693	5.9	45
186	Temporal trends in outpatient management of incident pulmonary embolism and associated mortality. <i>Thrombosis Research</i> , 2018 , 161, 111-116	8.2	14
185	Comparative effect of statins on the risk of incident Alzheimer disease. <i>Neurology</i> , 2018 , 90, e179-e187	6.5	21
184	Reply to P. Autier et al. <i>Journal of Clinical Oncology</i> , 2018 , 36, 831-832	2.2	
184	Reply to P. Autier et al. <i>Journal of Clinical Oncology</i> , 2018 , 36, 831-832 Beta-Blockers in COPD: A Methodological Review of the Observational Studies. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2018 , 15, 520-525	2.2	7
	Beta-Blockers in COPD: A Methodological Review of the Observational Studies. <i>COPD: Journal of</i>		7 87
183	Beta-Blockers in COPD: A Methodological Review of the Observational Studies. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2018 , 15, 520-525	2	
183	Beta-Blockers in COPD: A Methodological Review of the Observational Studies. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2018 , 15, 520-525 Cardiovascular disease and COPD: dangerous liaisons?. <i>European Respiratory Review</i> , 2018 , 27, Comparative effectiveness of LABA-ICS versus LAMA as initial treatment in COPD targeted by	9.8	8 ₇
183 182 181	Beta-Blockers in COPD: A Methodological Review of the Observational Studies. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2018 , 15, 520-525 Cardiovascular disease and COPD: dangerous liaisons?. <i>European Respiratory Review</i> , 2018 , 27, Comparative effectiveness of LABA-ICS versus LAMA as initial treatment in COPD targeted by blood eosinophils: a population-based cohort study. <i>Lancet Respiratory Medicine</i> , <i>the</i> , 2018 , 6, 855-862 Response to Comment on Suissa. Lower Risk of Death With SGLT2 Inhibitors in Observational	2 9.8 35.1	8 ₇
183 182 181	Beta-Blockers in COPD: A Methodological Review of the Observational Studies. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2018 , 15, 520-525 Cardiovascular disease and COPD: dangerous liaisons?. <i>European Respiratory Review</i> , 2018 , 27, Comparative effectiveness of LABA-ICS versus LAMA as initial treatment in COPD targeted by blood eosinophils: a population-based cohort study. <i>Lancet Respiratory Medicine</i> , <i>the</i> , 2018 , 6, 855-862 Response to Comment on Suissa. Lower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias? Diabetes Care 2018;41:6-10. <i>Diabetes Care</i> , 2018 , 41, e109-e110 Revisiting sex differences in outcomes in non-valvular atrial fibrillation: a population-based cohort	2 9.8 35.1 14.6	87 52 7
183 182 181 180	Beta-Blockers in COPD: A Methodological Review of the Observational Studies. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2018 , 15, 520-525 Cardiovascular disease and COPD: dangerous liaisons?. <i>European Respiratory Review</i> , 2018 , 27, Comparative effectiveness of LABA-ICS versus LAMA as initial treatment in COPD targeted by blood eosinophils: a population-based cohort study. <i>Lancet Respiratory Medicine</i> , <i>the</i> , 2018 , 6, 855-862 Response to Comment on Suissa. Lower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias? Diabetes Care 2018;41:6-10. <i>Diabetes Care</i> , 2018 , 41, e109-e110 Revisiting sex differences in outcomes in non-valvular atrial fibrillation: a population-based cohort study. <i>European Heart Journal</i> , 2017 , 38, 1473-1479 Statins in Multiple Myeloma: Survival Benefit or Immortal Time Bias?. <i>Journal of Clinical Oncology</i> ,	2 9.8 35.1 14.6 9.5	87 52 7 25

(2016-2017)

175	Pneumonia risk in asthma patients using inhaled corticosteroids: a quasi-cohort study. <i>British Journal of Clinical Pharmacology</i> , 2017 , 83, 2077-2086	3.8	28
174	Sulfonylureas and the Risks of Cardiovascular Events and Death: A Methodological Meta-Regression Analysis of the Observational Studies. <i>Diabetes Care</i> , 2017 , 40, 706-714	14.6	115
173	Drospirenone-Containing Oral Contraceptive Pills and the Risk of Venous Thromboembolism: An Assessment of Risk in First-Time Users and Restarters. <i>Drug Safety</i> , 2017 , 40, 583-596	5.1	8
172	Concurrent use of long-acting bronchodilators in COPD and the risk of adverse cardiovascular events. <i>European Respiratory Journal</i> , 2017 , 49,	13.6	43
171	Bias from depletion of susceptibles: the example of hormone replacement therapy and the risk of venous thromboembolism. <i>Pharmacoepidemiology and Drug Safety</i> , 2017 , 26, 554-560	2.6	26
170	The Risk of Sepsis with Inhaled and Oral Corticosteroids in Patients with COPD. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2017 , 14, 137-142	2	11
169	Patterns of long-term use of non-vitamin K antagonist oral anticoagulants for non-valvular atrial fibrillation: Quebec observational study. <i>Pharmacoepidemiology and Drug Safety</i> , 2017 , 26, 1546-1554	2.6	13
168	Long-Term Use of Long-Acting Insulin Analogs and Breast Cancer Incidence in Women With Type 2 Diabetes. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3647-3653	2.2	31
167	Pharmacologic Differences of Sulfonylureas and the Risk of Adverse Cardiovascular and Hypoglycemic Events. <i>Diabetes Care</i> , 2017 , 40, 1506-1513	14.6	50
166	Influenza Vaccination and Stillbirth Prevention in High-Income Countries: Is It Really That Effective?. <i>Clinical Infectious Diseases</i> , 2017 , 64, 1142-1143	11.6	
165	Prevalent new-user cohort designs for comparative drug effect studies by time-conditional propensity scores. <i>Pharmacoepidemiology and Drug Safety</i> , 2017 , 26, 459-468	2.6	89
164	Long-Acting Bronchodilator Initiation in COPD and the Risk of Adverse Cardiopulmonary Events: A Population-Based Comparative Safety Study. <i>Chest</i> , 2017 , 151, 60-67	5.3	34
163	The effect of statins on influenza-like illness morbidity and mortality. <i>Pharmacoepidemiology and Drug Safety</i> , 2017 , 26, 63-70	2.6	13
162	Association Between Incretin-Based Drugs and the Risk of Acute Pancreatitis. <i>JAMA Internal Medicine</i> , 2016 , 176, 1464-1473	11.5	65
161	The Use of Telmisartan and the Incidence of Cancer. American Journal of Hypertension, 2016, 29, 1358-1	3265	5
160	Association Between Achieved Low-Density Lipoprotein Levels and Major Adverse Cardiac Events in Patients With Stable Ischemic Heart Disease Taking Statin Treatment. <i>JAMA Internal Medicine</i> , 2016 , 176, 1105-13	11.5	52
159	Mortality Trends in Crohn's Disease and Ulcerative Colitis: A Population-based Study in QuBec, Canada. <i>Inflammatory Bowel Diseases</i> , 2016 , 22, 416-23	4.5	35
158	The INPULSIS trials of idiopathic pulmonary fibrosis treatment: explaining further discrepancies on exacerbations. <i>European Respiratory Journal</i> , 2016 , 47, 344-5	13.6	3

157	Inflammatory bowel disease and risk of mortality in COPD. European Respiratory Journal, 2016, 47, 135	7-63 46	13
156	Number needed to treat: enigmatic results for exacerbations in COPD. <i>European Respiratory Journal</i> , 2016 , 47, 354-5	13.6	2
155	Effect of Long-Acting Insulin Analogs on the Risk of Cancer: A Systematic Review of Observational Studies. <i>Diabetes Care</i> , 2016 , 39, 486-94	14.6	45
154	The cardiovascular safety of aromatase inhibitors and tamoxifen in post-menopausal women with breast cancer: A systematic review and meta-analysis of randomized controlled trials <i>Journal of Clinical Oncology</i> , 2016 , 34, 1573-1573	2.2	
153	Testosterone treatment and risk of venous thromboembolism: population based case-control study. <i>BMJ, The</i> , 2016 , 355, i5968	5.9	75
152	Statins and Risk of Rheumatoid Arthritis: A Nested Case-Control Study. <i>Arthritis and Rheumatology</i> , 2016 , 68, 2603-2611	9.5	23
151	Prescribing trends of attention-deficit hyperactivity disorder (ADHD) medications in UK primary care, 1995-2015. <i>British Journal of Clinical Pharmacology</i> , 2016 , 82, 858-68	3.8	66
150	Identifying Causes for Excess Mortality in Patients With Diabetes: Closer but Not There Yet. <i>Diabetes Care</i> , 2016 , 39, 1851-1853	14.6	16
149	Appropriate use of inhaled corticosteroids in COPD: the candidates for safe withdrawal. <i>Npj Primary Care Respiratory Medicine</i> , 2016 , 26, 16068	3.2	19
148	Phosphodiesterase Type 5 Inhibitors and the Risk of Melanoma Skin Cancer. <i>European Urology</i> , 2016 , 70, 808-815	10.2	24
147	Long-term vitamin K antagonists treatment patterns of Non-Valvular Atrial Fibrillation (NVAF): a population-based cohort study. <i>BMC Cardiovascular Disorders</i> , 2016 , 16, 84	2.3	7
146	Comparative effectiveness research with administrative health data in rheumatoid arthritis. <i>Nature Reviews Rheumatology</i> , 2016 , 12, 358-66	8.1	13
145	DPP-4 Inhibitors and Heart Failure: Some Reassurance, Some Uncertainty. <i>Diabetes Care</i> , 2016 , 39, 735-	714.6	18
144	Effect of Pre-Operative Use of Medications on the Risk of Surgical Site Infections in Patients Undergoing Cardiac Surgery. <i>Surgical Infections</i> , 2016 , 17, 557-62	2	2
143	Concurrent Use of Benzodiazepines and Antidepressants and the Risk of Motor Vehicle Accident in Older Drivers: A Nested Case-Control Study. <i>Neurology and Therapy</i> , 2015 , 4, 39-51	4.6	7
142	Long-acting Eagonists with vs without inhaled corticosteroids for COPD. <i>JAMA - Journal of the American Medical Association</i> , 2015 , 313, 305	27.4	2
141	The Quasi-cohort approach in pharmacoepidemiology: upgrading the nested case-control. <i>Epidemiology</i> , 2015 , 26, 242-6	3.1	43
140	Tramadol use and the risk of hospitalization for hypoglycemia in patients with noncancer pain. JAMA Internal Medicine, 2015, 175, 186-93	11.5	67

(2014-2015)

139	Number needed to treat: enigmatic results for exacerbations in COPD. <i>European Respiratory Journal</i> , 2015 , 45, 875-8	13.6	8
138	Risks of Cardiac Valve Regurgitation and Heart Failure Associated with Ergot- and Non-Ergot-Derived Dopamine Agonist Use in Patients with Parkinson's Disease: A Systematic Review of Observational Studies. <i>CNS Drugs</i> , 2015 , 29, 985-98	6.7	28
137	Increased incidence of inflammatory bowel disease in QuBec residents with airway diseases. <i>European Respiratory Journal</i> , 2015 , 45, 962-8	13.6	31
136	Tocilizumab in rheumatoid arthritis: a case study of safety evaluations of a large postmarketing data set from multiple data sources. <i>Seminars in Arthritis and Rheumatism</i> , 2015 , 44, 381-8	5.3	35
135	Incretin-based drugs and the risk of congestive heart failure. <i>Diabetes Care</i> , 2015 , 38, 277-84	14.6	39
134	Phenotypic heterogeneity of potentially curable non-small-cell lung cancer: cohort study with cluster analysis. <i>Journal of Thoracic Oncology</i> , 2015 , 10, 754-761	8.9	6
133	Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis. <i>Arthritis Research and Therapy</i> , 2015 , 17, 212	5.7	219
132	The use of antidepressants and the risk of chronic atrial fibrillation. <i>Journal of Clinical Pharmacology</i> , 2015 , 55, 423-30	2.9	6
131	Understanding and Avoiding Immortal-Time Bias in Gastrointestinal Observational Research. <i>American Journal of Gastroenterology</i> , 2015 , 110, 1647-50	0.7	48
130	Discontinuation of Inhaled Corticosteroids in COPD and the Risk Reduction of Pneumonia. <i>Chest</i> , 2015 , 148, 1177-1183	5.3	59
129	The INPULSIS enigma: exacerbations in idiopathic pulmonary fibrosis. <i>Thorax</i> , 2015 , 70, 508-10	7.3	12
128	Inhaled corticosteroids in COPD: the clinical evidence. European Respiratory Journal, 2015, 45, 525-37	13.6	111
127	The Number Needed to Treat: 25 Years of Trials and Tribulations in Clinical Research. <i>Rambam Maimonides Medical Journal</i> , 2015 , 6,	1.8	12
126	Antihypertensive agents acting on the renin-angiotensin system and the risk of sepsis. <i>British Journal of Clinical Pharmacology</i> , 2014 , 78, 1151-8	3.8	33
125	Use of statins and the risk of death in patients with prostate cancer. <i>Journal of Clinical Oncology</i> , 2014 , 32, 5-11	2.2	440
124	Initiation of warfarin in patients with atrial fibrillation: early effects on ischaemic strokes. <i>European Heart Journal</i> , 2014 , 35, 1881-7	9.5	77
123	Letter by Suissa and Galilregarding article, "Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA)". <i>Circulation</i> , 2014 , 130, e107	16.7	3
122	Metformin and cancer: mounting evidence against an association. <i>Diabetes Care</i> , 2014 , 37, 1786-8	14.6	67

121	Friday and weekend hospital stays: effects on mortality. European Respiratory Journal, 2014, 44, 627-33	13.6	10
120	Cardiac glycosides use and the risk of lung cancer: a nested case-control study. <i>BMC Cancer</i> , 2014 , 14, 573	4.8	3
119	Treatment patterns of venous thromboembolism in a real-world population: the Q-VTE study cohort. <i>Thrombosis Research</i> , 2014 , 134, 795-802	8.2	12
118	Incidence, mortality, and sex differences of non-valvular atrial fibrillation: a population-based study. <i>Journal of the American Heart Association</i> , 2014 , 3, e001402	6	24
117	Will SUMMIT reach the peak in COPD?. Thorax, 2014, 69, 405-7	7.3	8
116	The risk of thromboembolic events in kidney transplant patients. <i>Kidney International</i> , 2014 , 85, 1454-60	0 9.9	30
115	Incretin based drugs and risk of acute pancreatitis in patients with type 2 diabetes: cohort study. <i>BMJ, The</i> , 2014 , 348, g2780	5.9	53
114	Comment on Bordeleau et al. The association of basal insulin glargine and/or n-3 fatty acids with incident cancers in patients with dysglycemia. Diabetes Care 2014;37:1360-1366. <i>Diabetes Care</i> , 2014 , 37, e216	14.6	1
113	The use of metformin in patients with prostate cancer and the risk of death. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014 , 23, 2111-8	4	33
112	Time-related bias in administrative health database studies of disease incidence. <i>Epidemiology</i> , 2014 , 25, 930-2	3.1	2
111	Immortal time bias in observational studies of drug effects in pregnancy. <i>Birth Defects Research Part A: Clinical and Molecular Teratology</i> , 2014 , 100, 658-62		31
110	Oral corticosteroids and the risk of serious infections in patients with elderly-onset inflammatory bowel diseases. <i>American Journal of Gastroenterology</i> , 2014 , 109, 1795-802; quiz 1803	0.7	80
109	The use of antidepressants and the risk of idiopathic pulmonary arterial hypertension. <i>Canadian Journal of Cardiology</i> , 2014 , 30, 1633-9	3.8	10
108	Reply to D. Tural et al. <i>Journal of Clinical Oncology</i> , 2014 , 32, 2274	2.2	
107	Pharmacoepidemiology 2014 , 1875-1925		8
106	The use of metformin and the incidence of lung cancer in patients with type 2 diabetes. <i>Diabetes Care</i> , 2013 , 36, 124-9	14.6	66
105	Number needed to treat in COPD: exacerbations versus pneumonias. <i>Thorax</i> , 2013 , 68, 540-3	7.3	61
104	Concurrent use of diuretics, angiotensin converting enzyme inhibitors, and angiotensin receptor blockers with non-steroidal anti-inflammatory drugs and risk of acute kidney injury: nested case-control study. <i>BMJ, The</i> , 2013 , 346, e8525	5.9	220

(2012-2013)

103	Pulmonary arterial hypertension: epidemiology and registries. <i>Journal of the American College of Cardiology</i> , 2013 , 62, D51-9	15.1	338
102	Re: Daniel E. Spratt, Chi Zhang, Zachary S. Zumsteg, Xin Pei, Zhigang Zhang, Michael J. Zelefsky. Metformin and prostate cancer: reduced development of castration-resistant disease and prostate cancer mortality. Eur Urol 2013;63:709-16. <i>European Urology</i> , 2013 , 64, e28	10.2	1
101	The concurrent use of antithrombotic therapies and the risk of bleeding in patients with atrial fibrillation. <i>Thrombosis and Haemostasis</i> , 2013 , 109, 431-9	7	26
100	Response to comment on: Smiechowski et al. The use of metformin and the incidence of lung cancer in patients with type 2 diabetes. Diabetes Care 2013;36:124-129. <i>Diabetes Care</i> , 2013 , 36, e41	14.6	
99	Response to Bodmer et al. Metformin and the risk of cancer: time-related biases in observational studies. Diabetes care 2012;35:2665-2673. <i>Diabetes Care</i> , 2013 , 36, e86	14.6	4
98	Reply to Trezza et Al. <i>Clinical Infectious Diseases</i> , 2013 , 56, 1356-7	11.6	
97	The use of metformin and colorectal cancer incidence in patients with type II diabetes mellitus. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013 , 22, 1877-83	4	49
96	Inhaled corticosteroids in COPD and the risk of serious pneumonia. <i>Thorax</i> , 2013 , 68, 1029-36	7.3	296
95	Prescription of antidepressants and the risk of road traffic crash in the elderly: a case-crossover study. <i>British Journal of Clinical Pharmacology</i> , 2013 , 76, 810-5	3.8	17
94	The use of inhaled corticosteroids and the risk of adrenal insufficiency. <i>European Respiratory Journal</i> , 2013 , 42, 79-86	13.6	37
93	US Food and Drug Administration-mandated trials of long-acting Egonists safety in asthma: will we know the answer?. <i>Chest</i> , 2013 , 143, 1208-1213	5.3	12
92	Response. <i>Chest</i> , 2013 , 143, 580	5.3	1
91	Novel Approaches to Pharmacoepidemiology Study Design and Statistical Analysis 2013 , 383-395		
90	Aspirin use in prostate cancer and the risk of death and metastasis <i>Journal of Clinical Oncology</i> , 2013 , 31, 1518-1518	2.2	1
89	Number needed to treat is incorrect without proper time-related considerations. <i>Journal of Clinical Epidemiology</i> , 2012 , 65, 42-6	5.7	55
88	A net clinical benefit analysis of warfarin and aspirin on stroke in patients with atrial fibrillation: a nested case-control study. <i>BMC Cardiovascular Disorders</i> , 2012 , 12, 49	2.3	14
87	Dopamine agonist use and the risk of heart failure. <i>Pharmacoepidemiology and Drug Safety</i> , 2012 , 21, 34-41	2.6	31
86	Metformin and the risk of cancer: time-related biases in observational studies. <i>Diabetes Care</i> , 2012 , 35, 2665-73	14.6	363

85	Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality. <i>Thorax</i> , 2012 , 67, 957-63	7:3	402
84	Systemic effects of inhaled corticosteroids. Current Opinion in Pulmonary Medicine, 2012, 18, 85-9	3	32
83	The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study. <i>BMJ</i> , <i>The</i> , 2012 , 344, e3645	5.9	202
82	Randomized Trials Built on Sand: Examples from COPD, Hormone Therapy, and Cancer. <i>Rambam Maimonides Medical Journal</i> , 2012 , 3, e0014	1.8	16
81	Fluoroquinolones and the risk of serious arrhythmia: a population-based study. <i>Clinical Infectious Diseases</i> , 2012 , 55, 1457-65	11.6	59
80	Bronchodilator use and the risk of arrhythmia in COPD: part 1: Saskatchewan cohort study. <i>Chest</i> , 2012 , 142, 298-304	5.3	37
79	Bronchodilator use and the risk of arrhythmia in COPD: part 2: reassessment in the larger Quebec cohort. <i>Chest</i> , 2012 , 142, 305-311	5.3	70
78	The association between systemic glucocorticoid therapy and the risk of infection in patients with rheumatoid arthritis: systematic review and meta-analyses. <i>Arthritis Research and Therapy</i> , 2011 , 13, R1	3 5 :7	109
77	Time-window bias in case-control studies: statins and lung cancer. <i>Epidemiology</i> , 2011 , 22, 228-31	3.1	70
76	"Suicide-related events in patients treated with antiepileptic drugs": not an example of time-window bias. <i>Epidemiology</i> , 2011 , 22, 876-7	3.1	2
75	Long-term effects of insulin glargine on the risk of breast cancer. <i>Diabetologia</i> , 2011 , 54, 2254-62	10.3	85
74	Thiazolidinediones and the risk of incident congestive heart failure among patients with type 2 diabetes mellitus. <i>Pharmacoepidemiology and Drug Safety</i> , 2011 , 20, 785-96	2.6	18
73	Metformin and the incidence of prostate cancer in patients with type 2 diabetes. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011 , 20, 337-44	4	110
72	Gender differences in survival following hospitalisation for COPD. <i>Thorax</i> , 2011 , 66, 38-42	7.3	39
71	Risks of pneumonia in patients with asthma taking inhaled corticosteroids. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2011 , 183, 589-95	10.2	86
70	Mega trials in COPDclinical data analysis and design issues. <i>Pneumonologia I Alergologia Polska</i> , 2011 , 79, 227-31		2
69	Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study. <i>BMJ, The</i> , 2010 , 340, c2519	5.9	245
68	Co-morbidity in COPD: the effects of cardiovascular drug therapies. <i>Respiration</i> , 2010 , 80, 3-7	3.7	17

(2008-2010)

67	Use of venlafaxine compared with other antidepressants and the risk of sudden cardiac death or near death: a nested case-control study. <i>BMJ, The</i> , 2010 , 340, c249	5.9	42
66	Risk of glaucoma in elderly patients treated with inhaled corticosteroids for chronic airflow obstruction. <i>Pulmonary Pharmacology and Therapeutics</i> , 2010 , 23, 65-70	3.5	31
65	Inhaled corticosteroids and the risks of diabetes onset and progression. <i>American Journal of Medicine</i> , 2010 , 123, 1001-6	2.4	208
64	Infections requiring hospitalization in the abatacept clinical development program: an epidemiological assessment. <i>Arthritis Research and Therapy</i> , 2010 , 12, R67	5.7	47
63	The multitime case-control design for time-varying exposures. <i>Epidemiology</i> , 2010 , 21, 876-83	3.1	10
62	Combination therapy with sulfonylureas and metformin and the prevention of death in type 2 diabetes: a nested case-control study. <i>Pharmacoepidemiology and Drug Safety</i> , 2010 , 19, 335-42	2.6	22
61	Thiazolidinediones and the risk of incident strokes in patients with type 2 diabetes: a nested case-control study. <i>Pharmacoepidemiology and Drug Safety</i> , 2010 , 19, 343-50	2.6	11
60	Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes. <i>BMJ, The</i> , 2010 , 340, b5087	5.9	626
59	Calculation of number needed to treat. New England Journal of Medicine, 2009, 361, 424-5	59.2	28
58	Combined oral contraceptive use and the risk of systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2009 , 61, 476-81		72
57	Rheumatoid arthritis, its treatments, and the risk of tuberculosis in Quebec, Canada. <i>Arthritis and Rheumatism</i> , 2009 , 61, 300-4		69
56	Trends in the prescription of anti-diabetic medications in the United Kingdom: a population-based analysis. <i>Pharmacoepidemiology and Drug Safety</i> , 2009 , 18, 973-6	2.6	52
55	Effectiveness of combination therapies in asthma: an observational study. <i>Pulmonary Pharmacology and Therapeutics</i> , 2009 , 22, 194-8	3.5	4
54	The Transnational study of oral contraceptive cardiovascular safety: history and science. <i>Journal of Clinical Epidemiology</i> , 2009 , 62, 588-93	5.7	4
53	A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2008 , 10, R45	5.7	281
52	TNF-alpha antagonists and the prevention of hospitalisation for chronic obstructive pulmonary disease. <i>Pulmonary Pharmacology and Therapeutics</i> , 2008 , 21, 234-8	3.5	59
51	Immeasurable time bias in observational studies of drug effects on mortality. <i>American Journal of Epidemiology</i> , 2008 , 168, 329-35	3.8	131
50	Hematologic malignant neoplasms after drug exposure in rheumatoid arthritis. <i>Archives of Internal Medicine</i> , 2008 , 168, 378-81		92

49	Immortal time bias in pharmaco-epidemiology. American Journal of Epidemiology, 2008, 167, 492-9	3.8	1004
48	Medications to modify lung function decline in chronic obstructive pulmonary disease: some hopeful signs. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008 , 178, 322-3	10.2	18
47	Mortality benefit from unrestricted access to clopidogrel: too good to be true?. <i>Cmaj</i> , 2008 , 178, 425-7	3.5	1
46	Validating the effects of drug treatment on blood pressure in the General Practice Research Database. <i>Pharmacoepidemiology and Drug Safety</i> , 2008 , 17, 535-45	2.6	20
45	The risk of hospitalized infection in patients with rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2008 , 35, 387-93	4.1	159
44	Immortal time bias in observational studies of drug effects. <i>Pharmacoepidemiology and Drug Safety</i> , 2007 , 16, 241-9	2.6	358
43	Primer: administrative health databases in observational studies of drug effectsadvantages and disadvantages. <i>Nature Clinical Practice Rheumatology</i> , 2007 , 3, 725-32		129
42	Inhaled corticosteroids in chronic obstructive pulmonary disease. <i>Proceedings of the American Thoracic Society</i> , 2007 , 4, 535-42		42
41	Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2007 , 176, 162-6	10.2	306
40	Contribution of pharmacoepidemiological studies to the evaluation of treatment-related adverse events. <i>Joint Bone Spine</i> , 2006 , 73, 627-8	2.9	O
39	Statistical treatment of exacerbations in therapeutic trials of chronic obstructive pulmonary disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2006 , 173, 842-6	10.2	114
38	Use of first- and second-generation cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs and risk of acute myocardial infarction. <i>Circulation</i> , 2006 , 113, 1950-7	16.7	153
37	Prediction of acute and chronic complications by a new computer simulation model for type 1 and type 2 diabetes: the Diabetes Mel l it us Model (DMM). <i>Journal of Medical Economics</i> , 2006 , 9, 83-99	2.4	1
36	Diabetes Mel l it us Model (DMM): internal validation of a computer simulation model for type 1 and type 2 diabetes. <i>Journal of Medical Economics</i> , 2006 , 9, 69-82	2.4	1
35	Observational studies of inhaled corticosteroids in chronic obstructive pulmonary disease: misconstrued immortal time bias. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2006 , 173, 464; author reply 464-5	10.2	21
34	AuthorsItesponse: Warfarin, medicinal drugs and road traffic accidents. <i>British Journal of Clinical Pharmacology</i> , 2006 , 62, 628-628	3.8	2
33	Higher Prevalence of Prior Prostate Cancer in Patients Diagnosed with Chronic Myelogenous Leukemia <i>Blood</i> , 2006 , 108, 4795-4795	2.2	
32	Assessing a whiplash management model: a population-based non-randomized intervention study. Journal of Rheumatology, 2006 , 33, 581-7	4.1	19

(1995-2005)

31	Short-acting inhaled beta-2-agonists increased the mortality from chronic obstructive pulmonary disease in observational designs. <i>Journal of Clinical Epidemiology</i> , 2005 , 58, 92-7	5.7	22
30	Bias in observational study of the effectiveness of nasal corticosteroids in asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2005 , 115, 714-9	11.5	29
29	Cardiovascular morbidity and mortality in COPD. Chest, 2005, 128, 2640-6	5.3	285
28	Inhaled and nasal corticosteroid use and the risk of fracture. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2004 , 169, 83-8	10.2	125
27	Newer disease-modifying antirheumatic drugs and the risk of serious hepatic adverse events in patients with rheumatoid arthritis. <i>American Journal of Medicine</i> , 2004 , 117, 87-92	2.4	60
26	Use of lithium and the risk of injurious motor vehicle crash in elderly adults: case-control study nested within a cohort. <i>BMJ, The</i> , 2004 , 328, 558-9	5.9	19
25	Effectiveness of inhaled corticosteroids in chronic obstructive pulmonary disease: immortal time bias in observational studies. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2003 , 168, 49-5	3 ^{10.2}	225
24	The nested case-control study in cardiology. American Heart Journal, 2003, 146, 581-90	4.9	127
23	Inhaled corticosteroid use in asthma and the prevention of myocardial infarction. <i>American Journal of Medicine</i> , 2003 , 115, 377-81	2.4	53
22	The relation between initial symptoms and signs and the prognosis of whiplash. <i>European Spine Journal</i> , 2001 , 10, 44-9	2.7	101
21	Antihypertensives and myocardial infarction risk: the modifying effect of history of drug use. <i>Pharmacoepidemiology and Drug Safety</i> , 2001 , 10, 287-94	2.6	2
20	Ventricular arrhythmias and nonsedating antihistamines. <i>British Journal of Clinical Pharmacology</i> , 2000 , 49, 379-80	3.8	1
19	Low-dose inhaled corticosteroids and the prevention of death from asthma. <i>New England Journal of Medicine</i> , 2000 , 343, 332-6	59.2	842
18	Relative excess risk: an alternative measure of comparative risk. <i>American Journal of Epidemiology</i> , 1999 , 150, 279-82	3.8	39
17	First-time use of newer oral contraceptives and the risk of venous thromboembolism. <i>Contraception</i> , 1997 , 56, 141-6	2.5	169
16	Risk of ocular hypertension or open-angle glaucoma in elderly patients on oral glucocorticoids. <i>Lancet, The</i> , 1997 , 350, 979-82	40	124
15	Confounding by indication and channeling over time: the risks of beta 2-agonists. <i>American Journal of Epidemiology</i> , 1996 , 144, 1161-9	3.8	81
14	Binary regression with continuous outcomes. <i>Statistics in Medicine</i> , 1995 , 14, 247-55	2.3	17

13	The case-time-control design. <i>Epidemiology</i> , 1995 , 6, 248-53	3.1	196
12	The Saskatchewan oral contraceptive cohort study of oral contraceptive use and cardiovascular risks. <i>Pharmacoepidemiology and Drug Safety</i> , 1993 , 2, 33-49	2.6	6
11	A concurrent cohort study of oral contraceptive users from the VAMP research bank. <i>Pharmacoepidemiology and Drug Safety</i> , 1993 , 2, 51-63	2.6	15
10	Predicting arterial oxygenation during one-lung anaesthesia. <i>Canadian Journal of Anaesthesia</i> , 1992 , 39, 1030-5	3	77
9	Fenoterol and death from asthma. <i>Medical Journal of Australia</i> , 1992 , 157, 567-568	4	1
8	Statistical methods in pharmacoepidemiology. Principles in managing error. <i>Drug Safety</i> , 1991 , 6, 381-9	5.1	2
7	The use of biomarkers in the prediction of survival in patients with pulmonary carcinoma. <i>Cancer</i> , 1990 , 65, 2033-46	6.4	25
6	Unidirectional multiple comparisons of Poisson rates. <i>Statistics in Medicine</i> , 1989 , 8, 757-64	2.3	4
5	Are Uniformly Most Powerful Unbiased Tests Really Best?. American Statistician, 1984, 38, 204-206	5	7
4	Novel Approaches to Pharmacoepidemiology Study Design and Statistical Analysis811-829		2
3	Novel Approaches to Pharmacoepidemiology Study Design and Statistical Analysis785-805		24
2	Advanced Approaches to Controlling Confounding in Pharmacoepidemiologic Studies324-336		4
1	Advanced Approaches to Controlling Confounding in Pharmacoepidemiologic Studies868-891		6